LONDON (ShareCast) - (Sharecast News) - Life sciences group Aptamer on Monday announced a new fee-for-service development contract with an unnamed top 10 global pharma company.
The contract, valued at £112,000, represents "success-based repeat business with an existing partner", Aptamer said.

It will focus on the development of Aptamer's Optimer binders against two protein targets to support the partner's internal biomarker research.

"This work paves the way for additional revenue for ELISA assay development and builds on our proven success with a top 5 pharma partner in this space," said chief executive Arron Tolley.

Shares were up 0.4% at 1.05p by 1035 BST.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE